Drug Trial Radar · NCT01993186
Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Last checked: Nov 20, 2026Latest source record: Jun 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Feb 28, 2014
Primary completion
Sep 20, 2017
Study completion Sep 20, 2017
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the study are to evaluate the efficacy of UX007 compared to placebo as measured by the reduction from randomization to Week 8 in frequency of seizures and to evaluate the safety of UX007 via adverse event (AE) rates, laboratory values, and electrocardiogram (ECG).
Conditions
- Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions
UX007Drug
oral liquid
PlaceboDrug
oral liquid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Reduction From Baseline to Week 8 in Frequency of Total Seizures (Normalized to a 4-Week Rate)Time frame: Baseline, Week 8
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Discontinuations Due to TEAEs During the Placebo-Controlled PeriodTime frame: Weeks 0 to 8
- Number of Participants With TEAEs, Serious TEAEs and Discontinuations Due to TEAEs During the Extension PeriodTime frame: Weeks 9 to 52 plus 30 days
Locations
14 sites in 7 countries. Site status is shown where the registry gives one.
Children's Hospital Colorado - University of Colorado, Denver, School of Medicine
Aurora, Colorado
Miami Children's Research Institute
Miami, Florida
Neurology & Epilepsy Research Center
Orlando, Florida
Columbia University - Department of Neurology
New York, New York
Columbia University Medical Center
New York, New York
Cook Children's Hospital
Fort Worth, Texas
University of Texas Neurometabolic Clinic
Houston, Texas
Seattle Children's Hospital
Seattle, Washington
Melbourne Brain Centre
Heidelberg, Victoria, Australia
Service de Neurologie Pédiatrique et des Maladies Métaboliques - INSERM U1141 Hôpital Robert Debré - APHP
Paris, Cedex 19, France
Sheba University Medical Center
Tel Aviv, Israel
Unita' Operativa Neurologia Pediatrica e Malattie Muscolari Istituto "Giannina Gaslini"
Genova, Italy
Hospital Sant Joan de Deu
Barcelona, Spain
Newcastle University
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.